-+ 0.00%
-+ 0.00%
-+ 0.00%

Cogent to present pivotal APEX trial results for bezuclastinib in AdvSM at EHA 2026

PUBT·05/12/2026 13:31:32
Listen to the news
Cogent to present pivotal APEX trial results for bezuclastinib in AdvSM at EHA 2026
  • Cogent Biosciences flagged upcoming European Hematology Association Congress presentations of primary results from its pivotal APEX study of bezuclastinib in advanced systemic mastocytosis, scheduled for June 13, 2026.
  • The readout will outline how patients responded to treatment and how the drug was tolerated, positioning the program for potential regulatory and commercial planning if results support its risk-benefit profile.
  • Additional APEX data on disease biology will be presented June 12, 2026, extending the clinical package beyond headline efficacy and safety.
  • Separate preclinical work on CGT1145, a JAK2 V617F mutant-selective inhibitor, will be shown June 12, 2026, signaling pipeline expansion into genetically defined myeloproliferative disease targets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120930PRIMZONEFULLFEED9717887) on May 12, 2026, and is solely responsible for the information contained therein.